We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Intravitreal ranibizumab injections for neovascular age-related macular degeneration yielded similar outcomes in phakic and pseudophakic eyes, according to a study.
The retrospective review included 120 eyes of 110 patients with neovascular AMD; 75 eyes were phakic and 45 eyes were pseudophakic. Average follow-up was 18 months.
Phakic and pseudophakic patients received three monthly loading dose injections of Lucentis (ranibizumab, Genentech). Subsequent re-treatment was performed on an as-needed basis. Best corrected visual acuity, IOP, anterior chamber parameters and retinal images were assessed at 4 weeks and 3, 6, 9 and 12 months after injection.
Baseline mean BCVA was 0.88 in the phakic group and 0.86 in the pseudophakic group.
The average number of injections was 3.87 in the phakic group and 3.62 in the pseudophakic group; the between-group difference was statistically insignificant.
Study results showed that at final follow-up, mean BCVA was 0.75 in the phakic group and 0.74 in the pseudophakic group. Both improvements were statistically significant (P = .01 in the phakic group and P = .02 in the pseudophakic group), but the between-group difference in visual gain was insignificant.
Central macular thickness decreased significantly in both groups, but the between-group difference was not significant, the authors said.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.